MICARDIS HCT Rx
Generic Name and Formulations:
Telmisartan, hydrochlorothiazide; 40mg/12.5mg, 80mg/12.5mg, 80mg/25mg; tabs.
Boehringer Ingelheim Pharmaceuticals
Indications for MICARDIS HCT:
Hypertension (not as initial therapy).
Not for initial therapy. May be substituted for titrated components. BP not controlled on telmisartan 80mg/day: 80mg/12.5mg once daily. BP not controlled on HCTZ 25mg/day or BP controlled but hypokalemic: 80mg/12.5mg once daily. Both: may titrate up to 160mg/25mg after 2–4 weeks. Hepatic insufficiency or biliary obstruction: initially 40mg/12.5mg once daily; monitor closely. Severe renal (CrCl ≤30mL/min) or hepatic impairment: not recommended.
Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Salt/volume depletion; correct hypovolemia prior to initiation. Severe CHF. Renal or hepatic impairment. Renal artery stenosis. Asthma. Diabetes. Postsympathectomy. SLE. Gout. Acute myopia. Secondary angle-closure glaucoma. Monitor BP, electrolytes, and renal function. Elderly. Neonates. Pregnancy: avoid. Nursing mothers: not recommended.
See Contraindications. Concomitant ACE inhibitors (eg, ramipril): not recommended. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Digoxin, lithium toxicity. Adjust antidiabetic medications. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Hypokalemia with corticosteroids, ACTH. Orthostatic hypotension potentiated by alcohol, CNS depressants. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Potentiates other antihypertensives. May potentiate nondepolarizing muscle relaxants. May antagonize pressor amines. Reduced absorption with bile acid resins (eg, cholestyramine, colestipol). May interfere with parathyroid test.
Angiotensin II receptor blocker (ARB) + thiazide diuretic.
Upper respiratory tract infection, dizziness, sinusitis, diarrhea, fatigue, flu-like symptoms, back or abdominal pain, dyspepsia, erythema, vomiting, bronchitis, pharyngitis; electrolyte disturbances, orthostatic hypotension, hyperglycemia, hyperuricemia, adverse lipid values, angioedema, rhabdomyolysis (rare).
Tabs—3 x 10 (blister cards)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Genetic Variations Associated With Empathy Affect Psychiatric Conditions
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders
- Mortality Rates for Substance Use Disorders, Intentional Injuries Vary Widely By Country
- Facial Emotion Recognition Differentiates Behavioral Variant Frontotemporal Dementia From MDD
- The Challenge of Helping Uninsured Patients While Protecting Practice Finances
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed